ABOS logo

Acumen Pharmaceuticals (ABOS) Enterprise Value

Enterprise Value

$69.78 M
$0.000.00%

Thu, 06 Mar 2025 21:05:04 GMT


Summary


Performance

ABOS Enterprise Value Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

OtherABOSvaluationmetrics:

Enterprise Value Formula

Enterprise Value = Market Cap + Total Debt − Cash & Cash Equivalents

ABOS Enterprise Value Trends

PeriodPeriodEnterprise valueEnterprise valueMarket capMarket capPricePrice
todaytoday0.0%0.0%0.0%
1 m1 month-15.9%-15.1%-15.1%
3 m3 months-44.2%-42.6%-42.6%
6 m6 months-25.5%-44.1%-44.1%
ytdytd-28.4%-27.1%-27.1%
1 y1 year-67.9%-70.9%-72.0%
5 y5 years---

ABOS Enterprise Value Highs & Lows

PeriodPeriodHighHighCurrent vs highvs highLowLowCurrent vs lowvs low
1 m1-month-15.9%$68 M+2.6%
3 m3-month$130 M-46.5%$68 M+2.6%
6 m6-month$191 M-63.4%$68 M+2.6%
1 y1-year$227 M-69.2%$68 M+2.6%
3 y3-year$403 M-82.7%$13 M+445.2%
5 y5-year$742 M-90.6%$13 M+445.2%
alltimeall time$742 M-90.6%$13 M+445.2%

Acumen Pharmaceuticals Enterprise Value History

DateValue
2025
$69.78 M(-28.4%)
2024
$97.43 M(-45.9%)
DateValue
2023
$179.92 M(+96.6%)
2022
$91.54 M(-39.6%)
2021
$151.44 M

FAQ

  • What is Acumen Pharmaceuticals enterprise value?
  • What is the all time high enterprise value for Acumen Pharmaceuticals?
  • What is ABOS enterprise value year-to-date change?
  • What is Acumen Pharmaceuticals enterprise value year-on-year change?

What is Acumen Pharmaceuticals enterprise value?

The current enterprise value of ABOS is $69.78 M

What is the all time high enterprise value for Acumen Pharmaceuticals?

Acumen Pharmaceuticals all-time high enterprise value is $742.25 M

What is ABOS enterprise value year-to-date change?

Acumen Pharmaceuticals enterprise value has changed by -$27.64 M (-28.37%) since the beginning of the year

What is Acumen Pharmaceuticals enterprise value year-on-year change?

Over the past year, ABOS enterprise value has changed by -$147.78 M (-67.93%)